IDegLira Outperforms Glargine in One-Week Intensive Diabetes Therapy
This single-center randomized trial suggests a fixed-ratio basal insulin/GLP-1 receptor agonist combination accelerates and stabilizes short-term intensive glycemic control in overweight or obese type 2 diabetes compared with insulin glargine, both added to prandial aspart.
📅 Journal publication: Jul 13, 2026·Last updated: Oct 12, 2026
IDegLira outperforms insulin glargine for short-term diabetes control.
Managing glucose levels in overweight or obese patients with type 2 diabetes mellitus (T2DM) is challenging, and optimizing treatment is crucial for better outcomes. The study found that insulin degludec/liraglutide (IDegLira) combined with insulin aspart improved time in range to 84.03% versus 74.67% with insulin glargine (P = 0.007), required less insulin, and demonstrated faster target attainment. IDegLira provides better short-term glycemic control with improved stability and reduced insulin needs, making it a preferable option for intensive management in this patient population. IDegLira offers superior short-term glycemic control and stability compared to insulin glargine in severely hyperglycemic overweight or obese patients with T2DM.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Sun Y, Li X, Xu L Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus. Endocrine. 2026;91(1). doi:10.1007/s12020-026-04699-0
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.